BRPI0407213A - Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados - Google Patents

Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados

Info

Publication number
BRPI0407213A
BRPI0407213A BR0407213-8A BRPI0407213A BRPI0407213A BR PI0407213 A BRPI0407213 A BR PI0407213A BR PI0407213 A BRPI0407213 A BR PI0407213A BR PI0407213 A BRPI0407213 A BR PI0407213A
Authority
BR
Brazil
Prior art keywords
preeclampsia
elevation
determining
marinobufagenin
employing
Prior art date
Application number
BR0407213-8A
Other languages
English (en)
Inventor
Jules B Puschett
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of BRPI0407213A publication Critical patent/BRPI0407213A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302—Apparatus specially adapted for immunological test procedures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODO DE EMPREGO DA ELEVAçãO DE MARINOBUFAGENINA NA DETERMINAçãO DA PRESENçA DE PRé-ECLAMPSIA E APARELHOS RELACIONADOS". é fornecido um método para determinação da presença de pré-eclampsia onde a determinação é feita baseada no fato de haver uma elevação substancial na marinobufagenina que pode ser derivada do sangue ou urina e se tal elevação não existe o que conclui que não existe pré-eclampsia na paciente. O método pode ser praticado vantajosamente pelo emprego de urina, soro sang³íneo, plasma sang³íneo como o espécime n corporal que contém a proteína na determinação de se a paciente tem pré-eclampsia. O método pode incluir subseq³ente tratamento terapêutico da paciente. Um aparelho diagnóstico relacionado também é fornecido.
BR0407213-8A 2003-02-04 2004-02-02 Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados BRPI0407213A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44473003P 2003-02-04 2003-02-04
PCT/US2004/002802 WO2004071273A2 (en) 2003-02-04 2004-02-02 Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus

Publications (1)

Publication Number Publication Date
BRPI0407213A true BRPI0407213A (pt) 2006-02-07

Family

ID=32869296

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407213-8A BRPI0407213A (pt) 2003-02-04 2004-02-02 Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados

Country Status (7)

Country Link
US (1) US7439071B2 (pt)
EP (1) EP1592967A4 (pt)
JP (1) JP4625800B2 (pt)
AU (1) AU2004210650C1 (pt)
BR (1) BRPI0407213A (pt)
CA (1) CA2515012A1 (pt)
WO (1) WO2004071273A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
US7402313B2 (en) 2002-07-25 2008-07-22 Charles David Adair Method for controlling preeclampsia and eclampsia
CA2584151A1 (en) * 2004-10-19 2006-04-27 The Administrators Of The Tulane Educational Fund Method of treating human preeclampsia employing resibufagenin
US8038997B2 (en) 2005-06-27 2011-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-marinobufagenin antibodies and methods for their use
US20070257366A1 (en) * 2006-05-03 2007-11-08 Taiwan Semiconductor Manufacturing Company, Ltd. Barrier layer for semiconductor interconnect structure
US20080299602A1 (en) * 2007-05-31 2008-12-04 Puschett Jules B Methods of Employing Vascular Leakage to Diagnose a Capillary Leak Disorder
WO2010104646A1 (en) * 2009-03-09 2010-09-16 Scott and White Memorial Hospital Method of testing a patient for hypertension and related method of treatment and test kit
US20110008904A1 (en) * 2009-07-10 2011-01-13 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for determining if a patient has a traumatic brain injury and related apparatus
US20110207154A1 (en) * 2010-01-12 2011-08-25 Scott & White Healthcare Method for determination of marinobufagenin levels and compounds employable in such method
US20160299130A1 (en) * 2015-04-09 2016-10-13 Jules B. Puschett Telocinobufagin (TCINO) in the Diagnosis and Pathogenesis of Preeclampsia, Traumatic Brain Injury and Acute Respiratory Distress Syndrome
KR20210025063A (ko) * 2018-06-21 2021-03-08 씨티에스 바이오파마 엘엘씨 항-마리노부파게닌 항체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079171A (en) * 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
WO1990007122A1 (en) * 1988-12-14 1990-06-28 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
GB9213934D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Chemical compounds
US5770376A (en) 1992-12-02 1998-06-23 Biomedical Sciences Research Laboratories, Inc. Method of diagnosing and treating myocardial infarction and hypertension
WO1994012210A1 (en) * 1992-12-02 1994-06-09 Bagrov Alexei Y Anti-edlf antibody, composition thereof and method of diagnosing and treating cardiac arrhythmias, hypertension
US5543138A (en) 1994-03-10 1996-08-06 Genetics Institute, Inc. Methods of diagnosing and treating preeclampsia
GB9618931D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in pre-eclampsia and diabetes
US20030044856A1 (en) 1997-09-26 2003-03-06 Puschett Jules B. Method of determining volume dependent hypertension through protein reduction in phosphorylation or concentration and related apparatus
JPH11271222A (ja) * 1998-03-24 1999-10-05 Sekisui Chem Co Ltd 尿検査方法
US7794716B2 (en) * 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
US10167609B1 (en) 2018-01-12 2019-01-01 Cashman Dredging & Marine Contracting Co., LLC Carouseling articulated dredge and barge

Also Published As

Publication number Publication date
US20060263891A1 (en) 2006-11-23
WO2004071273A3 (en) 2005-02-03
EP1592967A2 (en) 2005-11-09
WO2004071273A2 (en) 2004-08-26
AU2004210650A1 (en) 2004-08-26
AU2004210650B2 (en) 2009-07-30
JP4625800B2 (ja) 2011-02-02
US7439071B2 (en) 2008-10-21
AU2004210650C1 (en) 2010-01-14
CA2515012A1 (en) 2004-08-26
JP2006517670A (ja) 2006-07-27
EP1592967A4 (en) 2007-06-20

Similar Documents

Publication Publication Date Title
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
EA200801071A1 (ru) Способы и композиции для применения в целях лечения пациентов с положительным по аутоантителам заболеванием
ATE553378T1 (de) Screening und behandlungsverfahren zur vorbeugung von frühgeburten
BRPI0407213A (pt) Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados
DE60326214D1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
BR112012008161B8 (pt) dispositivo que pode ser usado no corpo do usuário para prover vácuo para usos clínicos
BRPI0515758A (pt) dispositivo de ensaio de diagnóstico
ATE311148T1 (de) Chirurgische vorrichtungen
AR048031A1 (es) Metodos para estimar la necesidad y efectividad de la terapia con antioxidantes
CY1107901T1 (el) Μεθοδος προσδιορισμου για ασθενεια alzheimer
AU6933900A (en) Method, reagent and test cartridge for determining clotting time
Li et al. Morphine exacerbates postfracture nociceptive sensitization, functional impairment, and microglial activation in mice
WO2007092427A3 (en) Treatment of endotoxemia using endotoxin neutralizing agents
BRPI0518795A2 (pt) mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio
EP1563308A4 (en) METHOD AND KITS FOR TUMORIGENICITY DIAGNOSIS
EP1804789A4 (en) METHOD FOR TREATING PREECLAMPSY IN HUMANS WITH RESIBUFAGENIN
ATE529750T1 (de) Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target
JP2006517670A5 (pt)
Sanei et al. Inflammatory cells’ role in acetic acid-induced colitis
BRPI0508053A (pt) método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um composto
CY1107921T1 (el) Μεθοδος για την προγνωση της αθροιστικης επιβιωσης ασθενων
HUP0401953A2 (hu) Biotinszármazékok
BR0113646A (pt) Tratamento de distúrbios inflamatórios
WO2005030265A3 (en) Optical imaging of endometriosis
Romão et al. Impact of chronic pelvic pain on female sexual function

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.